Study shows NeuVax is effective when used with Herceptin to treat breast cancer
Jul 21, 2011
In breast cancer health news, the drug NeuVax was recently approved to treat breast cancer patients who are not ideal candidates for Herceptin treatments. Both drugs, produced by RXi Pharmaceuticals, are designed to stimulate cancer fighting T-cells.
A phase two study showed that NeuVax was effective when used in conjunction with Herceptin in aggressive breast cancer cases characterized by high HER2 protein levels. Herceptin is designed to treat patients with high HER2 levels, but only about one out of every four patients is eligible for exclusive Herceptin treatment.
The Federal Drug Administration has approved further clinical testing of NeuVax, which is administered via scheduled injections. Patients are given one shot per month for six months of treatment, followed by additional booster shots every six months thereafter as needed until they are cancer free.
The drug's success represents a significant achievement for the treatment of aggressive breast cancer, a disease that affects more than 200,000 women in the United States annually, killing more than 40,000 of them, according to the Centers for Disease Control.